Merck announced two appointments in two regions important for its biopharma business. Gary Zieziula will lead Merck's biopharma business in North America and Marc Horn will take the helm of the biopharma business in China. Gary Zieziula has been appointed President and Managing Director of the biopharma business in the U.S. and Canada, based in Rockland, Massachusetts, U.S., with immediate effect. In his role, he will be responsible for all areas of the company's business including driving overall strategic direction and maximizing growth across the region. Zieziula joined Merck in 2014 as Chief Commercial Officer in the U.S., having spent more than 30 years in the pharmaceutical industry, including senior level positions at MSD, Bristol Myers-Squibb, Roche and Amag Pharmaceuticals. Zieziula will report to Simon Sturge, Chief Operating Officer at the Healthcare business. Zieziula's predecessor, Paris Panayiotopoulos, accepted a new position outside of Merck at the end of 2015. Marc Horn will head the biopharma business of Merck in China as of April 1, 2016, as a Managing Director based in Beijing. He is currently the regional Chief Financial Officer (CFO) of Merck responsible for Eastern Asia, comprising China, Hong Kong, Japan, South Korea and Taiwan, for the three business sectors Healthcare, Life Science and Performance Materials. Horn has more than 16 years of management experience in finance in the pharmaceuticals and chemicals industry,
including positions at Bayer and Lanxess in Germany, China and Singapore. Allan Gabor, Mark Horn's predecessor, has been promoted to President of the Asian- Pacific region for Merck's biopharma business. In his new position, Horn will report to Gabor.